MW150   Click here for help

GtoPdb Ligand ID: 10524

Synonyms: compound 11 [PMID: 30978288] | compound 27 [WO2014145485A2] | compound 8 [PMID: 25676389] | MW-150 | MW01-18-150SRM
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: MW150 is a novel, pharmacologically selective p38α MAP kinase (MAPK14) inhibitor [2-3]. It is CNS-penetrant and is being pursued as a clinical lead for neurological disorders. MW150 is claimed in patent WO2014145485A2 that was filed by The Trustees Of Columbia University In The City Of New York [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 0
Rotatable bonds 3
Topological polar surface area 45.15
Molecular weight 381.2
XLogP 4.62
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CN1CCN(CC1)c1nnc(c(c1)c1ccncc1)c1ccc2c(c1)cccc2
Isomeric SMILES CN1CCN(CC1)c1nnc(c(c1)c1ccncc1)c1ccc2c(c1)cccc2
InChI InChI=1S/C24H23N5/c1-28-12-14-29(15-13-28)23-17-22(19-8-10-25-11-9-19)24(27-26-23)21-7-6-18-4-2-3-5-20(18)16-21/h2-11,16-17H,12-15H2,1H3
InChI Key CIIVUDIZZJLXCN-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
MW150 is being developed primarily as a disease-modifying drug for Alzheimer's disease and related dementias. It is being progressed to a Phase 1 safety and tolerability study that will be carried out in older volunteers without dementia. This study will include an ascending dose evaluation and will analyse MW150 pharmacokinetics. As of October 2019, no MW150 trial is registered on ClinicalTrials.gov.